Clinical trialNCT00591123CompletedPhase 2Interventional

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

SponsorTranslational Oncology Research InternationalEnrollment38Metastatic Adenocarcinoma of Gastric CardiaMetastatic Adenocarcinoma of the EsophagusUnresectable Adenocarcinoma of Gastric CardiaUnresectable Adenocarcinoma of the Esophagus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs. The main purpose of this study is to test the safety and effectiveness of this combination of chemotherapy drugs and to see how they affect your cancer. Another purpose of this study is to examine samples from your blood and tumor. This research will be done to better understand how subjects respond to treatment. Specifically, researchers will look at the way your genes and proteins respond to drugs like those used in this study.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Fairooz Kabbinavar, MD
UCLA - TORI
Study Director
clinicaltrials.gov ↗
J Randolph Hecht, MD
University of California, Los Angeles
Study Chair
clinicaltrials.gov ↗
Zev Wainberg, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Translational Oncology Research International (tori) Network
Los Angeles, California, United States
Ucla Jonsson Comprehensive Cancer Center
Los Angeles, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fluorouracil →Erlotinib →Folfox →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2007
Primary completion: 30 Jun 2011
Completion: 30 Sept 2015
Last update posted: 1 Oct 2021
Registered enrollment: 38
Registry id: NCT00591123

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.